TNFRSF9 and neoplasm: Kohrt went further, demonstrating that NK cells from patients with various B cell lymphomas and leukemias upregulated 4-1BB during culture with Rituximab-coated tumor cells, offering a proof of principle that Rituximab and α4-1BB work well as a dual therapy to treat B cell malignancies.